We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+3.44%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$327M
AUM Growth
-$2.9M
Cap. Flow
-$5.17M
Cap. Flow %
-1.58%
Top 10 Hldgs %
34.51%
Holding
107
New
22
Increased
29
Reduced
23
Closed
32

Top Buys

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$10.3M
2
MDT icon
Medtronic
MDT
+$7.09M
3
WMGI
Wright Medical Group Inc
WMGI
+$6.55M
4
AGN
Allergan plc
AGN
+$6.46M
5
MRK icon
Merck
MRK
+$6.16M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$8.12M
2
UHS icon
Universal Health Services
UHS
+$7.89M
3
BIIB icon
Biogen
BIIB
+$7.83M
4
BCR
CR Bard Inc.
BCR
+$5.49M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 91.54%
2 Real Estate 3.64%
3 Miscellaneous 2.35%
4 Financials 2.17%
5 Technology 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
76
Centene
CNC
$32.6B
– –
-10,800
Closed -$523K
DVAX
77
DELISTED
Dynavax Technologies
DVAX
– –
-50,500
Closed -$1.09M
EHC icon
78
Encompass Health
EHC
$12.2B
– –
-27,408
Closed -$1.01M
FOLD
79
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-261,000
Closed -$3.94M
GILD icon
80
Gilead Sciences
GILD
$183B
– –
-27,357
Closed -$2.22M
CBIO
81
Crescent Biopharma
CBIO
$638M
– –
-176
Closed -$246K
HALO icon
82
Halozyme
HALO
$12.3B
– –
-115,500
Closed -$2.01M
HSIC icon
83
Henry Schein
HSIC
$9.67B
– –
-53,423
Closed -$3.44M
IRTC icon
84
iRhythm Holdings
IRTC
$3.69B
– –
-44,300
Closed -$2.3M
NKTR icon
85
Nektar Therapeutics
NKTR
$2.3B
– –
-7,287
Closed -$2.62M
PFE icon
86
Pfizer
PFE
$157B
– –
-239,594
Closed -$8.12M
TEVA icon
87
Teva Pharmaceutical Industries Limited
TEVA
$44.9B
– –
-18,133
Closed -$319K
UHS icon
88
Universal Health Services
UHS
$10.7B
– –
-71,100
Closed -$7.89M
VRTX icon
89
Vertex Pharmaceuticals
VRTX
$130B
– –
-21,900
Closed -$3.33M
XBI icon
90
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-6,300
Closed -$545K
XRAY icon
91
Dentsply Sirona
XRAY
$2.02B
– –
-10,300
Closed -$616K
ZBH icon
92
Zimmer Biomet
ZBH
$18.5B
– –
-10,197
Closed -$1.16M
ZTS icon
93
Zoetis
ZTS
$30.2B
– –
-39,500
Closed -$2.52M
LUMO
94
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-4,011
Closed -$367K
NSTG
95
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-295,260
Closed -$4.77M
NVTA
96
DELISTED
Invitae Corporation
NVTA
– –
-85,200
Closed -$798K
AGRX
97
DELISTED
Agile Therapeutics
AGRX
– –
-221
Closed -$1.97M
LCI
98
DELISTED
Lannett Company, Inc.
LCI
– –
-7,000
Closed -$517K
ZSAN
99
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-1,182
Closed -$681K
DERM
100
DELISTED
Dermira, Inc.
DERM
– –
-65,015
Closed -$1.75M
1 2 3
4
5

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Endurant Capital Management held 107 positions worth $327M, down 0.88% from $330M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Endurant Capital Management's Q4 2017 filing shows 22 new, 29 increased, 23 reduced and 32 closed positions. Its largest new stake was Merck: 111,193 shares worth $5.97M. The largest sale was Pfizer, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Real Estate and Miscellaneous.

  • Endurant Capital Management's largest Q4 2017 buy was Merck: 111,193 shares worth $5.97M.
  • Endurant Capital Management added most to Walgreens Boots Alliance in Q4 2017, an estimated $10.3M increase.
  • Endurant Capital Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $7.83M.
  • Endurant Capital Management fully exited Pfizer in Q4 2017, selling an estimated $8.12M.
  • Endurant Capital Management's ten largest holdings make up 35% of its $327M portfolio in Q4 2017.
  • Endurant Capital Management opened 22 new positions and closed 32 in Q4 2017.
  • Endurant Capital Management's portfolio value fell 0.88% quarter-over-quarter to $327M.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.